1921
Volume 95, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Health-care workers (HCWs) will require Ebola virus vaccine (EVV) when it is introduced because of the high risk of exposure to the disease. Evaluations of factors that facilitate or limit vaccine uptake are critical for a successful vaccine program. Nigerian HCWs were interviewed to evaluate their knowledge, levels of acceptance, determinants of acceptance, and willingness to pay for EVV. The significance level was set at ≤ 0.05. None of the 193 participating HCWs had correct knowledge of EVV; 34.7% (67/193) of workers thought that EVV was an extract of the serum of Ebola virus patients. About 77.3% (51/66) of workers in a region that reported Ebola cases (Lagos) were willing to be vaccinated, compared with 4.7% (3/61) in Enugu and 13.6% (9/66) in Abia ( = 0.0001). After health education, the proportion of HCWs willing to receive EVV increased ( = 0.006) except for doctors ( < 0.1). The percentage of HCWs willing to pay for EVV was 86.4%, 72.1%, and 59% in Lagos, Enugu, and Abia, respectively. The workers had fears about EVV based on nonfactual assumptions. Therefore, the EVV introduction strategy should include a strong awareness campaign with adequate explanation about the content of EVV.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0206
2016-09-07
2017-11-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/95/3/654.html?itemId=/content/journals/10.4269/ajtmh.16-0206&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2016. Ebola Situation Report 20 January 2016. Available at: http://www.who.int/csr/disease/ebola/situation-reports/archive/en/. Accessed January 28, 2016.
  2. U.S. Centers for Disease Control and Prevention (CDC), 2003. Guidelines for Environmental Infection Control in Health-care Facilities. Available at: www.cdc.gov/hicpac/pdf/guidelines/eic_in_HCF_03.pdf. Accessed July 12, 2015.
  3. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere CG, , 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomized trial. Lancet 386: 857866.[Crossref]
  4. Savas E, Tanriverdi D, , 2010. Knowledge, attitudes and anxiety towards influenza A/H1N1 vaccination of health-care workers in Turkey. BMC Infect Dis 10: 281.[Crossref]
  5. Maltezou HC, Dedoukou X, Patrinos S, Maragos A, Poufta S, Gargalianos P, Lazanas M, , 2010. Determinants of intention to get vaccinated against novel (pandemic) influenza A H1N1 among health-care workers in a nationwide survey. J Infect 61: 252258.[Crossref]
  6. Chor JS, Ngai KL, Goggins WB, Wong MC, Wong SY, Lee N, Leung TF, Rainer TH, Griffiths SC, Chan PK, , 2009. Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys. BMJ 339: b3391.[Crossref]
  7. Ugwu EO, Obi SN, Ezechukwu PC, Okafor II, Ugwu AO, , 2013. Acceptability of human papilloma virus vaccine and cervical cancer screening among female health-care workers in Enugu, southeast Nigeria. NJCP 16: 249252.
  8. GhanaWeb, 2015. Doubts over Integrity of Ebola Trials. General News of Sunday, 5 July 2015. Available at: http://www.ghanaweb.com/GhanaHomePage/NewsArchive/Doubts-over-integrity-of-Ebola-trials-366573. Accessed May 4, 2015.
  9. Tagbo BN, Ughasoro MD, Esangbedo DO, , 2014. Parental acceptance of inactivated polio vaccine in southeast Nigeria: a qualitative cross-sectional interventional study. Vaccine 32: 61576162.[Crossref]
  10. Hoenen T, Feildmann H, , 2014. Ebola virus in west Africa and the use of experimental therapies or vaccine. BMC Biol 12: 80.[Crossref]
  11. Qiu X, Wong G, Andet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP, , 2014. Reversion of advanced Ebola virus disease in non-human primates with Zmapp. Nature 514: 4753.
  12. Bisgard KM, Rhodes P, Hardy IR, Litkina IL, Filatov NN, Monisov AA, Wharton M, , 2000. Diphtheria toxoid vaccine effectiveness: a case-control study in Russia. J Infect Dis 181 (Suppl 1): S184S187.[Crossref]
  13. Deivanayagam N, Nedunchelian K, Ahamed SS, Rathnam SR, , 1993. Clinical efficacy of trivalent oral poliomyelitis vaccine: a case-control study. Bull World Health Organ 71: 307309.
  14. Strategic Advisory Group of Experts Working Group, 2014. Report of the SAGE Working Group on Vaccine Hesitancy. Available at: www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf. Accessed April 12, 2013.
  15. Larson HJ, Jarrett C, Eckersberger E, Smith D, Patterson P, , 2014. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012. Vaccine 32: 21502159.[Crossref]
  16. Williams SE, Rothman RL, Offit PA, Schaffner W, Sullivan M, Edwards KM, , 2013. A randomized trial to increase acceptance of childhood vaccines by vaccine-hesitant parents: a pilot study. Acta Paediatr 13: 475480.[Crossref]
  17. Constantine NA, Jerman P, , 2007. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 40: 108115.[Crossref]
  18. Information Nigeria, 2009. The Nigerian States by Population. Available at: www.informationng.com. Accessed November 23, 2015.
  19. Ughasoro MD, Esangbedo DO, Tagbo BN, Mejeha IC, , 2015. Acceptability and willingness-to-pay for a hypothetical Ebola virus vaccine in Nigeria. PLoS Negl Trop Dis 9: e0003838.[Crossref]
  20. Cutilli CC, , 2010. Seeking health information: what sources do your patients use? Orthop Nurs 29: 214219.
  21. Redmond N, Baer H, Clark CR, Lipsitz S, Hicks LS, , 2010. Sources of health information related to preventive health behaviors in a national study. Am J Prev Med 38: 620627.[Crossref]
  22. Puts MT, Tapscott B, Fitch M, Howell D, Monette J, Wan-Chow-Wah D, Krzyzanowska M, Leighl NB, Springall E, Alibhai SM, , 2015. A systematic review of factors influencing older adults' decision to accept or decline cancer treatment. Cancer Treat Rev 241: 197215.[Crossref]
  23. Kong KA, Yoon SH, Cho SJ, Kim HW, Kim KH, , 2014. Public acceptance and willingness to hepatitis A vaccination in children aged 7–18 years in Republic of Korea. J Korean Med Sci 29: 15281535.[Crossref]
  24. Hadisoemarto PF, Castro MC, , 2013. Public acceptance and willingness-to-pay for a future Dengue vaccine: a community-based survey in Bandung, Indonesia. PLoS Negl Trop Dis 7: e2427.[Crossref]
  25. Onwujekwe O, Hanson K, Uzochukwu B, , 2012. Are the poor differently benefiting from provision of priority health services? A benefit incidence analysis in Nigeria. Int J Equity Health 11: 70.[Crossref]
  26. Zhou F, Shefer A, Wenge J, Messonnier M, Wang LY, Lopez A, Moore M, Murphy TV, Cortese M, Rodewald L, , 2014. Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics 133: 19.[Crossref]
  27. Enugu State Ministry of Health (EMOH), 2007. Pricelist for Services in Public Health Facilities in Enugu State. Ministry Enugu, Nigeria: EMOH.
  28. Wagstaff A, van Doorslaer E, Paci P, , 1991. On the measurement of inequalities in health. Soc Sci Med 35: 545557.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0206
Loading
/content/journals/10.4269/ajtmh.16-0206
Loading

Data & Media loading...

  • Received : 15 Mar 2016
  • Accepted : 23 May 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error